Screener
Immunome IMNM Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from public offerings | — | 172,500 |
| Payment of offering costs | (364) | (10,485) |
| Proceeds from exercise of stock options | 229 | 213 |
| Net cash (used in) provided by financing activities | (135) | 162,228 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (70,789) | 114,262 |
| Cash and cash equivalents and restricted cash at beginning of period | 653,692 | 143,451 |
| Cash and cash equivalents and restricted cash at end of period | $582,903 | $257,713 |
| Reconciliation of cash and cash equivalents and restricted cash: |
Item 1. Financial Statements.
FAQ
- What is Immunome's financing cash flow?
- Immunome (IMNM) reported financing cash flow of -$135K in Q1 2026.
- How has Immunome's financing cash flow changed year-over-year?
- Immunome's financing cash flow decreased by 100.1% year-over-year, from $162.23M to -$135K.
- What is the long-term trend for Immunome's financing cash flow?
- Over 3 years (2021 to 2025), Immunome's financing cash flow has grown at a 184.0% compound annual growth rate (CAGR), from $27.96M to $640.41M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Immunome's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude